Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., commonly referred to as Ono Pharma, is a prominent player in the biopharmaceutical industry, headquartered in Osaka, Japan. Founded in 1717, the company has a rich history of innovation, focusing on the research, development, and commercialisation of novel therapeutics, particularly in oncology, immunology, and pain management. Ono Pharma is renowned for its flagship product, Opdivo (nivolumab), a groundbreaking immunotherapy that has transformed cancer treatment paradigms. The company’s commitment to advancing healthcare is reflected in its robust pipeline and strategic partnerships, positioning it as a leader in the global pharmaceutical market. With a strong presence in Japan and expanding operations in North America and Europe, Ono Pharmaceutical continues to make significant strides in delivering unique and effective solutions for patients worldwide.
DitchCarbon Score
How does Ono Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ono Pharmaceutical's score of 70 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ono Pharmaceutical's reported carbon emissions
In 2023, Ono Pharmaceutical reported total greenhouse gas emissions of approximately 67,000 tonnes CO2e for Scope 1, 9,500 tonnes CO2e for Scope 2, and 41,100 tonnes CO2e for Scope 3 emissions. The total emissions for Scope 1 and 2 combined reached about 16,200 tonnes CO2e. Notably, the company has set ambitious targets to achieve carbon neutrality for its Scope 1 and 2 emissions by 2025, moving the original target date from 2050 to 2035. This commitment includes a reduction of absolute Scope 1 and 2 emissions by 55% by FY2030, with a long-term goal of reaching zero emissions by FY2035. Ono Pharmaceutical's Scope 3 emissions, which include categories such as capital goods and business travel, totalled approximately 41,100 tonnes CO2e in 2023. The company aims to reduce these emissions by 30% by FY2030 and 60% by FY2050, using FY2017 as the baseline year. The company's climate commitments are aligned with the Science Based Targets initiative (SBTi), which validates their targets as consistent with the reductions required to limit global warming to 1.5°C. These initiatives reflect Ono Pharmaceutical's proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 00,000,000 | - | - | - | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ono Pharmaceutical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
